top of page

Pioneering Treatments for Neurological Disorders 

Neuromity Therapeutics is developing next-generation therapies using Deuterium-Enabled Chiral Switching (DECS).

Using our DECS technology platform, we extract the best from drugs to deliver new, best-in-class medicines.

Our Science

Through a combination of site-specific deuteration and chiral chemistry, we are creating superior drugs that target fundamental elements of neurological diseases like Major Depressive Disorder (MDD).

Our Strategy

We are developing novel, patent-protected NCEs with superior activity and/or tolerability profiles utilizing the 505(b)(2) regulatory pathway to expedite and de-risk approval.

About Us

Our expert leadership team has over 30 years of documented successes in applying chiral chemistry to improve existing drugs. 

Better Medicines,
Happier Patients

Neuromity Therapeutics, Inc. is a Boston-based biopharmaceutical company dedicated to making better drugs for serious neurological disorders.


Our patent-protected lead drug candidate, NTY-184, is based on bupropion, the active ingredient in the widely-prescribed antidepressant, Wellbutrin®. In pre-clinical studies, NTY-184 has a better activity profile and tolerability compared to bupropion. With FDA's guidance, we have defined an expeditious and de-risked path to approval for Major Depressive Disorder (MDD).

bottom of page